Re: question on M. Brucer's P-32 vignette

[Carol Marcus <csmarcus@ucla.edu>]

At 08:17 PM 1/18/2004, Jaro wrote:

>What I would like to know is whether P-32 therapy is still unavailable in

>the US,





Dear Jaro and Radsafers:



P-32 therapy has always been available in the U.S.  The NRC tried at one 

point to forbid it for FDA-unapproved indications, but the nuclear medicine 

community, with the help of the head of the NRC Medical Program and the 

FDA, prevailed.  This was one of the situations that led to NRC's 

"Radiopharmacy Rule", in which NRC stopped trying to tell nuclear 

physicians and nuclear pharmacists what drugs they could or couldn't use, 

which indications could be treated with which drugs, and how drugs should 

be prepared.



While there is still a contingent of vicious bureaucrats at NRC who keep 

trying to undercut the Radiopharmacy Rule with specific license conditions 

that take away the value of the rule, so far we have stopped them.  Maybe 

one day the Commissioners will wise up and get rid of these people, 

although I doubt that they have the administrative competence to do so.



Ciao, Carol 



************************************************************************

You are currently subscribed to the Radsafe mailing list. To

unsubscribe, send an e-mail to Majordomo@list.vanderbilt.edu  Put the

text "unsubscribe radsafe" (no quote marks) in the body of the e-mail,

with no subject line. You can view the Radsafe archives at

http://www.vanderbilt.edu/radsafe/